Evidence map›Paper›PMID 42812236›Full record

ArticleFrontiers in oncology2026

Case Report: MR-guided adaptive stereotactic body radiotherapy for splenic metastases: a case series of technical feasibility and early clinical outcomes.

D Tan, L Edwards, H L Byrne, T Liang, K Biggerstaff, E Leong, T Lim, K Rahim, H Tan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

D TanGenesis Care Murdoch, Murdoch, WA, Australia.
L EdwardsGenesis Care Murdoch, Murdoch, WA, Australia.
H L ByrneGenesis Care Murdoch, Murdoch, WA, Australia.
T LiangGenesis Care Murdoch, Murdoch, WA, Australia.
K BiggerstaffGenesis Care Murdoch, Murdoch, WA, Australia.
E LeongGenesis Care Murdoch, Murdoch, WA, Australia.
T LimGenesis Care Murdoch, Murdoch, WA, Australia.
K RahimGenesis Care Murdoch, Murdoch, WA, Australia.
H TanGenesis Care Murdoch, Murdoch, WA, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case series of four patients with five splenic metastases treated with stereotactic body radiation therapy (SBRT) using a 1.5-T Unity (Elekta AB, Stockholm, Sweden) magnetic resonance linear accelerator (MR-Linac). While SBRT is a standard of care for the treatment of oligometastatic disease, splenic SBRT is not well established due to its rarity. MRI-guided adaptive radiotherapy (MRgART) offers superior soft tissue visualization and the unique ability to adapt treatment plans in real time. In our series, splenic oligometastases originated from primary malignancies of melanoma, colorectal adenocarcinoma, and non-small-cell lung cancer. Prescription doses ranged from 40 to 50 Gy in five fractions, with gross tumor volumes between 2.4 and 22.7 cm

Indexed as

MRI radiation therapyoligometastasesSBRT (stereotactic body radiation therapy)spleenstereotacic radiation

Identifiers

PMID42812236
PMCPMC13619394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.